ARTA
MRSN

A.R.T. Advisors’s Mersana Therapeutics MRSN Stock Holding History

A.R.T. Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,932
Closed -$76K – 1581
2019
Q3 		$76K Buy
1,932
+1,116
+137% +$81.1K ﹤0.01% 1285
2019
Q2 		$83K Sell
816
-221
-21% -$26K ﹤0.01% 1218
2019
Q1 		$136K Buy
+1,037
New +$130K 0.01% 1138

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

A.R.T. Advisors's MRSN Position: Q4 2019 in Review

A.R.T. Advisors sold out of Mersana Therapeutics (MRSN) in Q4 2019, closing a stake of 1,932 shares — an estimated $76K sold.

A.R.T. Advisors first reported a position in MRSN in Q1 2019 and held it in 3 quarters. The position peaked at $136K in Q1 2019. 69 funds tracked by Wall St. Rank hold MRSN as of Q4 2019.

  • A.R.T. Advisors reported no remaining Mersana Therapeutics position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 1,932 Mersana Therapeutics shares in Q4 2019, an estimated $76K.
  • A.R.T. Advisors first reported a position in Mersana Therapeutics in Q1 2019 and held it in 3 quarters.
  • A.R.T. Advisors's Mersana Therapeutics position peaked at $136K in Q1 2019.
  • 69 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.